Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results

Benzinga Earnings

08/04

Inspire Medical Systems Inc (NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.

Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.

Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.

“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.

Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.

These analysts made changes to their price targets on Inspire Medical following earnings announcement.

Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.
Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.

Considering buying INSP stock? Here’s what analysts think:

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2656284555"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656284555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656284555?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656284555","market":"hk","top_or_hot":-1,"title":"Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> Inc </strong>(NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.</p>\n<p>Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.</p>\n<p>Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.</p>\n<p>“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.</p>\n<p>Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Inspire Medical following earnings announcement.</p>\n<ul>\n<li>Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.</li>\n<li>Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.</li>\n</ul>\n<p><strong>Considering buying INSP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"310\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-300x91.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-768x233.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-04 20:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> Inc </strong>(NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.</p>\n<p>Inspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.</p>\n<p>Inspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.</p>\n<p>“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.</p>\n<p>Inspire Medical shares jumped 14.6% to $59.85 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Inspire Medical following earnings announcement.</p>\n<ul>\n<li>Baird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.</li>\n<li>Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.</li>\n</ul>\n<p><strong>Considering buying INSP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"310\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-1024x310.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-300x91.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69-768x233.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/04081309/image-69.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/60903644/inspire-medical-systems-analysts-raise-their-forecasts-following-strong-q2-results","article_id":"2656284555","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656284555","pubTimestamp":1785845680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"INSPI beats expectations, raises FY26 guidance. Analysts raise price targets to $59 &amp; $60. Stock jumps 14.6% in pre-market trading. #INSP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","INSP":"Inspire Medical Systems","BK4082":"医疗保健设备","BK4167":"医疗保健技术"},"translate_title":"Inspire Medical Systems 分析师在第二季度业绩强劲后上调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":1.5},"content_text":"Inspire Medical Systems Inc (NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.\nInspire Medical Systems reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of a loss of 27 cents per share. The company reported quarterly sales of $200.581 million which beat the analyst consensus estimate of $194.671 million.\nInspire Medical raised its FY2026 adjusted EPS guidance from $0.75-$1.25 to $1.05-$1.45 and also increased its sales guidance from $825.000 million-$875.000 million to $835.000 million-$875.000 million.\n“Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.\nInspire Medical shares jumped 14.6% to $59.85 in pre-market trading.\nThese analysts made changes to their price targets on Inspire Medical following earnings announcement.\n\nBaird analyst Mike Polark maintained the stock with a Neutral and raised the price target from $54 to $59.\nPiper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $55 to $60.\n\nConsidering buying INSP stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}